Elutia

Q2 FY2026 EarningsQ2 FY26 results missed consensus on the top and bottom lines, with revenue of $2.43M falling below the $2.90M estimate due to a $0.7M production disruption in the SimpliDerm business. GAAP Gross Margin of 59.6% beat the 54.0% consensus, driven by a transition to direct sales in the Cardiovascular segment and improved efficiencies. The GAAP Net Loss of $7.65M was wider than the $6.60M expected, primarily due to accelerated R&D spending on the NXT-41x program. However, the company secured up to $26M in non-dilutive capital, extending its runway through the anticipated 2028 commercial launch of NXT-41x.